DOI: http://dx.doi.org/10.18203/2349-3933.ijam20163724

A study of the sociodemographic, clinical, pathological and radiological profile of lung cancer in a tertiary care center

Silpa Kshetrimayum, Anand Srivastava, Surya Kant, Ajay Kumar Verma, Ved Prakash, Darshan Kumar Bajaj, Nuzhat Husain, M. L. B. Bhatt

Abstract


Background: Lung cancer now constitutes the majority of all cancer diagnosis in the world. It has the most unfavourable prognosis accounting for the maximum number of cancer related deaths worldwide. The objective of this study was to study the complete profile of lung cancer. Prevalence of EGFR mutation in adenocarcinoma.

Methods: 116 lung cancer patients were enrolled. They were subjected to diagnostic procedures like transthoracic FNAC/biopsy, bronchoscopy, thoracoscopy, closed pleural biopsy, lymph node FNAC/biopsy, besides routine blood and sputum examinations and CECT thorax. Data was analysed retrospectively after 1 year.

Results: Most patients presented in the sixth decade. Mean duration of symptoms was 7.24 months. 62% patients were smokers, 54.3% were exposed to non-smoke tobacco, 18.9% to environmental tobacco smoke (ETS) and biomass fuel. Mass as the single radiological lesion was the most common radiological finding. Pleural effusion was seen in 51.7% patients and was more common in females. Liver (3.4%) and brain (5.9%) were the most common sites of metastasis. EGFR mutation was positive in 34.2% of adenocarcinoma. Exon 19 deletion was more common. ALK was positive in 1 patient. Maximum number of patients (70.7%) presented in stage 4. Transthoracic biopsy could diagnose 61.2% of all lung cancers. Adenocarcinoma was the most common diagnosis (60.3%) and was more common in females and non-smokers.

Conclusions: Most patients present in an advanced stage. Adenocarcinoma now seems to be the most common histological subtype of lung cancer in India. EGFR mutation is common in the Indian population. Biomass fuel exposure is a significant risk factor in females. Bronchoscopy is the procedure of choice for diagnosing central tumours and transthoracic FNAC and Biopsy for peripheral tumours.


Keywords


Adenocarcinoma, EGFR, Lung cancer, NSCLC, Smokers

Full Text:

PDF

References


Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45.

Cancer notification in India: an update. Aggarwal H, Kumar P. South Asian J Cancer. 2014;3(4):236-7.

Behera D, Balmugesh T. Indoor air pollution as a risk factor for lung cancer in women. J Assoc Physicians India. 2005;53:190-2.

Gray N. The consequences of the unregulated cigarette. Tob Control. 2006;15(5):405-8.

Daniel R, John HM, Robert T. Influence of Type of Cigarette on Peripheral versus Central Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:576.

Behera D. Epidemiology of lung cancer – Global and Indian perspective. JIACM. 2012;13(2):131-7.

Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 651 cases. Ann Oncol 2002;13:1087-93.

Navin P, Balbir M, Nirmalchand K. Clinico pathological Profile of Patients with Lung Cancer Visiting Chest and TB Hospital Amritsar. Sch. J. App. Med. Sci. 2015;3(2D):802-9.

Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Res J. 2004;24(6).

Ito M, Niho S, Nihei K, Yoh K, Ohmatsu H, Ohe Y. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer. BMC Cancer. 2012;12:27.

Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis. 2011;3:183-8.

Yu YH, Liao CC. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J of Thorac Oncol. 2011;6(1):32-7.

Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. J Clin Oncol. 2001;19(5):1358-62.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.

Bruce N, Dherani M. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 study. Thorax. 2015;70(5):433-41.

Flounders J. Superior vena cava syndrome. Oncol Nurs Forum. 2003;30(4):E84-8.

Nunnelee JD. Superior vena cava syndrome. J Vasc Nurs. 2007;25(1):2-5.

Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology.Medicine (Baltimore). 2006;85(1):37-42.

Behera D, Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci. 2004;46:269-81.

Mosmann MP. Solitary pulmonary nodule and (18) F-FDG PET/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras. 2016;49(1):35-42.

Cella D, Davis K, Breitbart W, Curt G. Fatique Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385-91.

Kaqohashi K, Satoh H. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol. 2003;20(1):25-8.

Srikanth SG, Jayakumar PN, Chandrashekar HS. CT features of intracranial metastases of unknown primaries.Neurol India. 2002;50:282-5.

Dey A, Biswas D, Saha SK, Kundu S, Sengupta A. Comparison study of clinic radiological profile of primary lung cancer cases: An Eastern India experience. Indian J Cancer. 2012;49:89-95.

Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346:1971-7.

Kushwaha R, Shashikala P, Hirmath S, Basavaraj H G. Cells in pleural fluid and their value in differential diagnosis. J Cytol. 2008;25:138-43.

Varol Y, Varol U. Primary lung cancer coexisting with active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2014;18(9):1121-5.

Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e142S-65S.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.

Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med 2004;350(21):2129-39.

Li M, Zhang Q, Liu L, Liu Z, Zhou L, Wang Z. The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma. 2011;58(1):74-81.

Puey L, Paul M. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423-32.

Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002;165:508-13.

Houston KA, Henley SJ, Li J, White MC, Richards TB. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer. 2014;86(1):22-8.

William T, Brambilla E. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85.